News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Paolo Tarantino: Terrific 2 weeks for breast oncology
Paolo Tarantino/X
Jan 29, 2025, 22:05

Paolo Tarantino: Terrific 2 weeks for breast oncology

Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X:

“What a terrific 2 weeks for breast oncology:

  • Dato-DXd approved for HR+/HER2- mBC
  • T-DXd approval expanded to HER2-ultralow disease
  • inavolisib triplet announced to prolong OS

And I can bet that some more practice changing data is being submitted to ASCO25 before midnight.”

ASCO25 breast oncology cancer OncoDaily Oncology Paolo Tarantino
Special Coverage
Blog
Jan 29, 2025, 22:05
Preliminary Safety, Antitumor Activity, and ctDNA Changes with Zoldonrasib in KRAS G12D PDAC
Blog
Jan 29, 2025, 22:05
Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
Blog
Jan 29, 2025, 22:05
Zainab Shinkafi-Bagudu: The HPV vaccine does NOT cause infertility in girls or women
Blog
Jan 29, 2025, 06:59
Yüksel Ürün: The impact of comorbidities on survival in cancer patients receiving ICIs
Blog
Jan 29, 2025, 22:05
Shernan Holtan: Launching ''Transplant and Cell Therapy University'' at Roswell Park Comprehensive Cancer Center
Blog
Jan 29, 2025, 22:05
Katsuaki Maehara: Immunotherapy trials in resectable NSCLC
Blog
Jan 29, 2025, 22:05
Paolo Tarantino: Terrific 2 weeks for breast oncology
Blog
Jan 29, 2025, 22:05
Vivek Subbiah: AACR elections are here!
Blog
Jan 29, 2025, 22:05
Sandy Duarte: Cancer Ramblings is now officially released into the world
Blog
Jan 29, 2025, 22:05
Cancer care must go beyond the disease to truly make a difference
Blog
Jan 29, 2025, 21:39
Jeff Yang: Assessing Lung Cancer Screening Eligibility of patients in the Boston Lung Cancer Study
Science
Jan 29, 2025, 21:39
Endoscopically injected oncolytic virus OBP-301 in medically inoperable esophageal cancer